#2Vipul Jairath(UWO: University of Western Ontario)H-Index: 14
Last. Simon Travis(John Radcliffe Hospital)H-Index: 7
view all 3 authors...
SummaryBackground Vedolizumab specifically recognises the α4β7 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression. Aim To review the safety of vedolizumab and summarise post-marketing data to assess if any safety concerns that differ from registration trials have emerged. Method A systematic bibliographic search identified six registration trials and nine cohort studies. Results Integrated data from registration trials included 2830 ...